Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial

• Ting Li ,

  Contributed equally to this work with: Ting Li, Biyun Wang

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯
• Biyun Wang ,

  Contributed equally to this work with: Ting Li, Biyun Wang

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯
• Zhonghua Wang,

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯
• Joseph Ragaz,

  Affiliation Faculty of Medicine, School of Population & Public Health, University of British Columbia, Vancouver, B.C., V6T 1Z4, Canada

  ⨯
• Jian Zhang,

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯
• Si Sun,

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯
• Jun Cao,

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯
• Fangfang Lv,

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯
• Leiping Wang,

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯
• Sheng Zhang,

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯
• Chen Ni,

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯
• Zhenhua Wu,

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯
• Jie Xie,

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯
• Xichun Hu

  * E-mail: huxicun@gmail.com

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

  ⨯